title: The effect of prazosin on patients with symptoms of benign prostatic hypertrophy.
abstract: OBJECTIVE
  To evaluate the effect of prazosin on the symptoms of benign prostatic hypertrophy for patients of general practitioners.
  
  
  METHODS
  Eighty-two general practitioner patients from 317 who were identified as being eligible for inclusion in the trial. They were randomly allocated to receive either prazosin or placebo for the first 3 month arm then crossed-over for the second 3 months.
  
  
  RESULTS
  Seventy-six patients completed the trial. An analogue scale of patient rating of symptoms showed a statistically significant decrease in symptoms for patients taking prazosin when compared with patients taking placebo, regardless of the order in which they had been administered. A total symptom score and an obstructive symptom score for benign prostatic hypertrophy showed a statistically significant difference between the two treatments at 4 weeks. A difference was still apparent at 8 and 12 weeks but it was not statistically significant. No difference was detected for irritative symptoms.
  
  
  CONCLUSIONS
  Prazosin may have a limited place in the management of benign prostatic hypertrophy.
authors.affiliation: Research and Health Promotion Unit, Royal Australian College of General Practitioners.
authors.forename: I D
authors.initials: ID
authors.lastname: Steven
authors.forename: G A
authors.initials: GA
authors.lastname: Coffey
authors.forename: N M
authors.initials: NM
authors.lastname: Graham
authors.forename: J
authors.initials: J
authors.lastname: Wlodarczyk
authors.forename: P
authors.initials: P
authors.lastname: Curtis
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D011224:Prazosin